MariMed Inc. (OTCMKTS:MRMD – Get Free Report) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 16,030 shares, a decline of 75.0% from the May 31st total of 64,138 shares. Based on an average daily volume of 1,406,144 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are short sold.
MariMed Price Performance
MRMD stock opened at $0.07 on Friday. MariMed has a 52 week low of $0.06 and a 52 week high of $0.23. The company has a quick ratio of 0.34, a current ratio of 0.95 and a debt-to-equity ratio of 1.67. The company has a fifty day simple moving average of $0.08 and a two-hundred day simple moving average of $0.08. The firm has a market capitalization of $28.02 million, a P/E ratio of -2.34 and a beta of 1.30.
MariMed (OTCMKTS:MRMD – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). MariMed had a negative net margin of 7.82% and a negative return on equity of 5.00%. The business had revenue of $39.48 million during the quarter, compared to analysts’ expectations of $38.75 million. Analysts anticipate that MariMed will post -0.04 earnings per share for the current fiscal year.
About MariMed
MariMed Inc is a multi?state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult?use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.
The company’s product portfolio includes branded flower, pre?rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.
Featured Articles
- Five stocks we like better than MariMed
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
